NCT07596901PHASE1, PHASE2Recruiting

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Aurinia Pharmaceuticals Inc.

Start Date

4/22/2026

Completion Date

3/2/2029

Summary

This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.

Eligibility Criteria

Age Range: 18 years to 85 years

Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeeding or intending to become pregnant during the Study * Additional exclusion criteria are defined in the protocol

Interventions

DRUG

Aritinercept

OTHER

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Myasthenia Gravis, Generalized

Locations

Aurinia Investigational Site

Altamonte Springs, Florida 32714

United States

Aurinia Investigational Site

Boca Raton, Florida 33487

United States

Aurinia Investigational Site

Miami, Florida 33173

United States